International Journal of Molecular Sciences Tau, bridging the gap between Alzheimer's and Parkinson's diseases Shining infrared light on amy
International Journal of Molecular Sciences Tau, bridging the gap between Alzheimer's and Parkinson's diseases Shining infrared light on amyloid structures in neurodegenerative proteinopathies.. 22(7)
Ämnestermer:
Medical and Health Sciences, Basic Medicine, Neurosciences, Medicin och hälsovetenskap, Medicinska och farmaceutiska grundvetenskaper, Neur
Alzheimer’s disease affects millions of lives worldwide. This terminal disease is characterized by the formation of amyloid aggregates, so
Alzheimer’s disease affects millions of lives worldwide. This terminal disease is characterized by the formation of amyloid aggregates, so-called amyloid oligomers. These oligomers are composed of β-sheet structures, which are believed to be neurotoxic. However, the actual secondary structure that contributes most to neurotoxicity remains unknown. This lack of knowledge is due to the challenging nature of characterizing the secondary structure of amyloids in cells. To overcome this and investigate the molecular changes in proteins directly in cells, we used synchrotron-based infrared microspectroscopy, a label-free and non-destructive technique available for in situ molecular imaging, to detect structural changes in proteins and lipids. Specifically, we evaluated the formation of β-sheet structures in different monogenic and bigenic cellular models of Alzheimer’s disease that we generated for this study. We report on the possibility to discern different amyloid signatures directly in cells using infrared microspectroscopy and demonstrate that bigenic (amyloid-β, α-synuclein) and (amyloid-β, Tau) neuron-like cells display changes in β-sheet load. Altogether, our findings support the notion that different molecular mechanisms of amyloid aggregation, as opposed to a common mechanism, are triggered by the specific cellular environment and, therefore, that various mechanisms lead to the development of Alzheimer’s disease.
Lund University, Profile areas and other strong research environments, Strategic research areas (SRA), NanoLund: Centre for Nanoscience, Lunds universitet, Profilområden och andra starka forskningsmiljöer, Strategiska forskningsområden (SFO), NanoLund: Centre for Nanoscience, Originator, Lund University, Faculty of Medicine, Department of Experimental Medical Science, Medical Microspectroscopy, Lunds universitet, Medicinska fakulteten, Institutionen för experimentell medicinsk vetenskap, Medicinsk mikrospektroskopi, Originator, Lund University, Profile areas and other strong research environments, Strategic research areas (SRA), MultiPark: Multidisciplinary research focused on Parkinson´s disease, Lunds universitet, Profilområden och andra starka forskningsmiljöer, Strategiska forskningsområden (SFO), MultiPark: Multidisciplinary research focused on Parkinson´s disease, Originator, Lund University, Faculty of Medicine, Department of Experimental Medical Science, Neuroinflammation, Lunds universitet, Medicinska fakulteten, Institutionen för experimentell medicinsk vetenskap, Neuroinflammation, Originator, Lund University, Faculty of Medicine, Department of Experimental Medical Science, Experimental Dementia Research, Lunds universitet, Medicinska fakulteten, Institutionen för experimentell medicinsk vetenskap, Experimentell demensforskning, Originator, Lund University, Faculty of Medicine, Department of Experimental Medical Science, Neural Plasticity and Repair, Lunds universitet, Medicinska fakulteten, Institutionen för experimentell medicinsk vetenskap, Neural plasticitet och reparation, Originator, Lund University, Faculty of Science, LINXS - Institute of advanced Neutron and X-ray Science, Lunds universitet, Naturvetenskapliga fakulteten, LINXS Institute of advanced Neutron and X-ray Science, Originator